| Chemogenetics revealed: DREADD occupancy and activation via converted clozapine JL Gomez, J Bonaventura, W Lesniak, WB Mathews, P Sysa-Shah, ... Science 357 (6350), 503-507, 2017 | 996 | 2017 |
| Allosteric interactions between agonists and antagonists within the adenosine A2A receptor-dopamine D2 receptor heterotetramer J Bonaventura, G Navarro, V Casadó-Anguera, K Azdad, W Rea, ... Proceedings of the National Academy of Sciences 112 (27), E3609-E3618, 2015 | 162 | 2015 |
| Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability J Bonaventura, S Lam, M Carlton, MA Boehm, JL Gomez, O Solís, ... Molecular psychiatry 26 (11), 6704-6722, 2021 | 159 | 2021 |
| High-potency ligands for DREADD imaging and activation in rodents and monkeys J Bonaventura, MAG Eldridge, F Hu, JL Gomez, M Sanchez-Soto, ... Nature communications 10 (1), 4627, 2019 | 145 | 2019 |
| Cocaine Inhibits Dopamine D2 Receptor Signaling via Sigma-1-D2 Receptor Heteromers G Navarro, E Moreno, J Bonaventura, M Brugarolas, D Farre, D Aguinaga, ... PloS one 8 (4), e61245, 2013 | 142 | 2013 |
| Ultrapotent chemogenetics for research and potential clinical applications CJ Magnus, PH Lee, J Bonaventura, R Zemla, JL Gomez, MH Ramirez, ... Science 364 (6436), eaav5282, 2019 | 136 | 2019 |
| Allosteric mechanisms within the adenosine A2A–dopamine D2 receptor heterotetramer S Ferré, J Bonaventura, D Tomasi, G Navarro, E Moreno, A Cortés, ... Neuropharmacology 104, 154-160, 2016 | 107 | 2016 |
| l-DOPA-treatment in primates disrupts the expression of A2A adenosine–CB1 cannabinoid–D2 dopamine receptor heteromers in the caudate nucleus J Bonaventura, AJ Rico, E Moreno, S Sierra, M Sánchez, N Luquin, ... Neuropharmacology 79, 90-100, 2014 | 101 | 2014 |
| l-DOPA disrupts adenosine A2A–cannabinoid CB1–dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies A Pinna, J Bonaventura, D Farré, M Sánchez, N Simola, J Mallol, C Lluís, ... Experimental neurology 253, 180-191, 2014 | 97 | 2014 |
| Essential Control of the Function of the Striatopallidal Neuron by Pre-coupled Complexes of Adenosine A2A-Dopamine D2 Receptor Heterotetramers and … S Ferre, J Bonaventura, W Zhu, C Hatcher-Solis, J Taura, C Quiroz, ... Frontiers in pharmacology 9, 243, 2018 | 88 | 2018 |
| Key role of the dopamine D4 receptor in the modulation of corticostriatal glutamatergic neurotransmission J Bonaventura, C Quiroz, NS Cai, M Rubinstein, G Tanda, S Ferré Science advances 3 (1), e1601631, 2017 | 59 | 2017 |
| Adenosine receptors as markers of brain iron deficiency: implications for restless legs syndrome C Quiroz, S Gulyani, W Ruiqian, J Bonaventura, R Cutler, V Pearson, ... Neuropharmacology 111, 160-168, 2016 | 56 | 2016 |
| Useful pharmacological parameters for G-protein-coupled receptor homodimers obtained from competition experiments. Agonist–antagonist binding modulation V Casadó, C Ferrada, J Bonaventura, E Gracia, J Mallol, EI Canela, ... Biochemical pharmacology 78 (12), 1456-1463, 2009 | 49 | 2009 |
| Opioid–galanin receptor heteromers mediate the dopaminergic effects of opioids NS Cai, C Quiroz, J Bonaventura, A Bonifazi, TO Cole, J Purks, AS Billing, ... The Journal of clinical investigation 129 (7), 2730-2744, 2019 | 48 | 2019 |
| Ultrastructural localization of DREADD s in monkeys A Galvan, J Raper, X Hu, JF Paré, J Bonaventura, CT Richie, ... European Journal of Neuroscience 50 (5), 2801-2813, 2019 | 46 | 2019 |
| Evidence for the heterotetrameric structure of the adenosine A2A–dopamine D2 receptor complex V Casadó-Anguera, J Bonaventura, E Moreno, G Navarro, A Cortés, ... Biochemical Society Transactions 44 (2), 595-600, 2016 | 39 | 2016 |
| Designer receptors exclusively activated by designer drugs approach to treatment of sleep-disordered breathing T Fleury Curado, H Pho, C Freire, MR Amorim, J Bonaventura, LJ Kim, ... American journal of respiratory and critical care medicine 203 (1), 102-110, 2021 | 35 | 2021 |
| Motivational valence is determined by striatal melanocortin 4 receptors AM Klawonn, M Fritz, A Nilsson, J Bonaventura, K Shionoya, ... The Journal of Clinical Investigation 128 (7), 3160-3170, 2018 | 31 | 2018 |
| Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease X Guitart, J Bonaventura, W Rea, M Orrú, L Cellai, I Dettori, F Pedata, ... Neurobiology of disease 96, 47-53, 2016 | 28 | 2016 |
| The SARS-CoV-2 spike protein binds and modulates estrogen receptors O Solis, AR Beccari, D Iaconis, C Talarico, CA Ruiz-Bedoya, ... Science Advances 8 (48), eadd4150, 2022 | 21 | 2022 |
